Pharmacokinetics and pilot efficacy of a mesalamine rectal gel in distal ulcerative colitis

被引：5

作者：

Aumais G. ^{[1
]}

Lefebvre M. ^{[2
]}

Massicotte J. ^{[2
]}

Tremblay C. ^{[2
]}

Kasbo J. ^{[2
]}

Brunet J.-S. ^{[2
]}

Cardinal C. ^{[3
,4
]}

Grace M. ^{[5
]}

Spénard J. ^{[3
,4
]}

机构：

[1] Hôpital Maisonneuve-Rosemont, Montréal, Que.

[2] Algorithme Pharma Inc., Montréal, Que.

[3] Department of Pharmacology, Faculty of Medicine, Université de Montréal, Montréal, Que.

[4] Axcan Pharma, Mont Saint-Hilaire, Que. J3H 6C4

[5] Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alta.

来源：

Drugs in R & D | 2005年 / 6卷 / 1期

关键词：

Ulcerative Colitis; Mesalazine; Disease Activity Index; Rectal Biopsy; Urinary Recovery;

D O I：

10.2165/00126839-200506010-00005

中图分类号：

学科分类号：

摘要：

[No abstract available]

引用

页码：41 / 46

页数：5

共 14 条

[1]

William C.N., Haber G., Aquino J.A., Double-blind placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories, Dig. Dis. Sci., 32, 12 SUPPL., (1987)

[2]

Ngo Y., Rambaud J.C., 5-aminosalicylic acid enema (Pentasa) versus hydrocortisone acetate foam (Proctocort) for the treatment of outbreaks of proctitis and cryptogenetic proctosigmoiditis: A comparative randomized multicenter trial, Gastroenterol. Clin. Biol., 16, 6-7, pp. 558-563, (1992)

[3]

Ngo Y., Gelinet J.M., Ivanovic A., Et al., Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis: A doubleblind versus placebo randomised trial, Gastroenterol. Clin. Biol., 16, 10, pp. 782-786, (1992)

[4]

Farup P.G., Hovde O., Halvorsen F.A., Et al., Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis: A comparison of the efficacy and practicality of two topical treatment regimens, Scand. J. Gastroenterol., 30, 2, pp. 164-170, (1995)

[5]

Hanauer S., Good L., Goodman M.W., Et al., Long-term use of mesalamine suppositories in remission maintenance of ulcerative proctitis, Am. J. Gastroenterol., 95, 7, pp. 1749-1754, (2000)

[6]

Aumais G., Lefebvre M., Tremblay C., Et al., Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500mg suppositories to healthy volunteers and ulcerative proctitis patients, Aliment Pharmacol. Ther., 17, pp. 93-97, (2003)

[7]

Gionchetti P., Venturi A., Rizzello C., Et al., Retrograde colonic spread of a new mesalamine rectal enema in patients with distal ulcerative colitis, Aliment. Pharmacol. Ther., 11, 4, pp. 679-684, (1997)

[8]

Gionchetti P., Ardizzone S., Benvenuti M., Et al., A new mesalamine gel enema in the treatment of left-sided ulcerative colitis: A randomised controlled multicentre trial, Aliment Pharmacol. Ther., 13, pp. 381-388, (1999)

[9]

Aumais G., Lefebvre G., Spenard J., Rectal tissue, plasma, and urine concentrations of mesalamine (5-ASA) after single and multiple administration of 4g enema to ulcerative colitis patients, Gastroenterology, 4 SUPPL. 122, (2002)

[10]

Fried G., Giacomelli R., Pimpo M., Et al., Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis, Gut, 47, 3, pp. 410-414, (2000)

← 1 2 →